Subscribe

Newron Pharmaceuticals S.p.A. (NP5.DE)

EUR12.45 -0.25 (-1.97%)
IT XETRA Healthcare Biotechnology
Address via Ludovico Ariosto 21 20091
Bresso, IT
CEO Stefan Weber
Website newron.com
IPO 2019-07-04
ISIN IT0004147952

Explore sections of this company profile

Also trades on Deutsche Börse · NP5.DE (EUR) London Stock Exchange · 0QOI.L (CHF) Other OTC · NWPHF (USD) Swiss Exchange · NWRN.SW (CHF)
Description

Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR12.45 -0.25 (-1.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4.8K
Beta
0.75
Float Shares
17.91M
Free Float %
86.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-5.61% -0.66% -4.42% -26.81% -20.01% -42.50% +92.26% +271.32% +523.46% +173.47% +173.47%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
12.45
Quality scores
Altman Z-Score
6.18
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -62.8% Q4'25: +103.2% (vs Q4'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    -178.8% Q4'25: -26.9% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +156.7% Q4'25: -18.5% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -24.7% Q4'25: -83.6% (vs Q4'23)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q4'25: +1,311.0% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +7.5% Q4'25: +11.9% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -8.37× Q4'25: -1.60× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.78) × ERP
WACC = 89% × Ke + 11% × Kd (11.6%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 12.45
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2006
actual 		Dec 2007
actual 		Dec 2008
actual 		Dec 2009
actual 		Dec 2010
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
4 Rev. Ana.
1 EPS Ana. 		Dec 2027
4 Rev. Ana.
1 EPS Ana. 		Dec 2028
2 Rev. Ana.
1 EPS Ana. 		Dec 2029
3 Rev. Ana.
1 EPS Ana. 		Dec 2030
3 Rev. Ana.
1 EPS Ana.
Revenue
1.19M
est: 2.87M (-58.4%)
4.02M
est: 4.31M (-6.6%)
3.93M
est: 4.51M (-12.7%)
2.54M
est: 6.18M (-58.9%)
806.0K
est: 1.17M (-30.9%)
280.0K
est: 4.67M (-94.0%)
8.92M
est: 9.54M (-6.5%)
3.54M
est: 8.14M (-56.5%)
1.56M
est: 14.11M (-89.0%)
2.38M
est: 3.02M (-21.1%)
6.73M
est: 5.03M (+33.8%)
13.43M
est: 14.47M (-7.2%)
4.03M
est: 6.98M (-42.3%)
7.04M
est: 7.90M (-10.9%)
5.26M
est: 5.65M (-6.9%)
5.76M
est: 6.10M (-5.5%)
6.09M
est: 6.53M (-6.7%)
9.06M
est: 9.13M (-0.9%)
51.39M
est: 52.11M (-1.4%)
19.13M
est: 20.16M (-5.1%)
24.62M
9.73M – 41.41M
+22.1% YoY
30.99M
9.04M – 55.31M
+25.9% YoY
120.90M
37.69M – 213.34M
+290.1% YoY
164.00M
51.12M – 289.39M
+35.6% YoY
170.00M
52.99M – 299.98M
+3.7% YoY
EBITDA
-16.73M
est: -2.00M (-734.9%)
-13.47M
est: -23.73M (+43.2%)
-18.05M
est: -8.65M (-108.6%)
-24.03M
est: -19.32M (-24.4%)
-21.49M
est: -4.46M (-381.9%)
-6.34M
est: -86.20M (+92.6%)
-2.63M
est: -12.85M (+79.5%)
-7.74M
est: -1.89M (-308.6%)
-11.18M
est: -13.16M (+15.0%)
-17.60M
est: -1.76M (-899.9%)
-15.29M
est: -42.98M (+64.4%)
-4.05M
est: -53.44M (+92.4%)
-14.79M
est: -2.57M (-474.7%)
-19.38M
est: -16.38M (-18.4%)
-18.35M
est: -22.39M (+18.1%)
-12.22M
est: -25.86M (+52.8%)
-13.32M
est: -24.32M (+45.2%)
-11.83M
est: -24.19M (+51.1%)
25.94M
est: -26.05M (+199.6%)
-4.55M
est: -11.02M (+58.7%)
-13.46M
-22.64M – -5.32M
-22.1% YoY
-16.94M
-30.24M – -4.94M
-25.9% YoY
-66.09M
-116.63M – -20.60M
-290.1% YoY
-89.66M
-158.21M – -27.95M
-35.6% YoY
-92.94M
-163.99M – -28.97M
-3.7% YoY
EBIT
-16.97M
est: -2.01M (-746.3%)
-13.68M
est: -25.19M (+45.7%)
-18.32M
est: -14.31M (-28.0%)
-24.56M
est: -25.11M (+2.2%)
-21.67M
est: -4.64M (-367.0%)
-6.43M
est: -86.56M (+92.6%)
-2.70M
est: -13.24M (+79.6%)
-7.78M
est: -2.30M (-237.7%)
-11.22M
est: -13.49M (+16.9%)
-24.97M
est: -1.93M (-1,194.7%)
-15.07M
est: -41.01M (+63.2%)
-5.22M
est: -54.65M (+90.5%)
-14.96M
est: -1.82M (-720.4%)
-19.59M
est: -16.71M (-17.3%)
-18.56M
est: -22.99M (+19.3%)
-12.44M
est: -26.55M (+53.2%)
-13.53M
est: -24.97M (+45.8%)
-12.03M
est: -24.84M (+51.6%)
25.75M
est: -26.75M (+196.3%)
-4.73M
est: -11.07M (+57.3%)
-13.52M
-22.75M – -5.34M
-22.1% YoY
-17.02M
-30.38M – -4.96M
-25.9% YoY
-66.40M
-117.17M – -20.70M
-290.1% YoY
-90.08M
-158.95M – -28.08M
-35.6% YoY
-93.37M
-164.76M – -29.10M
-3.7% YoY
Net Income
-16.40M
est: -55.69M (+70.6%)
-11.09M
est: -24.66M (+55.0%)
-16.36M
est: -11.60M (-41.1%)
-23.48M
est: -22.43M (-4.7%)
-20.55M
est: -4.44M (-363.2%)
-6.45M
est: -82.20M (+92.2%)
-2.38M
est: -13.18M (+82.0%)
-7.10M
est: -2.03M (-249.7%)
-10.10M
est: -12.31M (+18.0%)
-22.82M
est: -1.74M (-1,214.5%)
-15.24M
est: -38.35M (+60.3%)
-5.28M
est: -54.34M (+90.3%)
-15.04M
est: -2.22M (-578.3%)
-20.21M
est: -16.77M (-20.5%)
-21.00M
est: -22.23M (+5.5%)
-14.90M
est: -25.67M (+42.0%)
-17.49M
est: -24.14M (+27.5%)
-16.22M
est: -24.02M (+32.4%)
15.84M
est: -25.86M (+161.3%)
-13.33M
est: -12.08M (-10.3%)
-19.31M
-38.50M – -2.03M
-59.8% YoY
-20.27M
-40.43M – -2.13M
-5.0% YoY
-44.63M
-89.00M – -4.70M
-120.2% YoY
82.65M
8.70M – 164.80M
+285.2% YoY
91.23M
9.60M – 181.91M
+10.4% YoY
SGA
6.62M
est: 1.83M (+262.1%)
9.58M
est: 2.75M (+248.5%)
9.37M
est: 2.87M (+226.0%)
8.55M
est: 3.94M (+117.1%)
6.52M
est: 744.5K (+776.3%)
6.95M
est: 2.98M (+133.4%)
4.21M
est: 6.09M (-30.8%)
3.81M
est: 6.85M (-44.4%)
3.67M
est: 11.72M (-68.7%)
4.34M
est: 1.16M (+275.1%)
5.10M
est: 3.21M (+59.1%)
6.09M
est: 9.23M (-34.0%)
5.56M
est: 3.83M (+45.1%)
10.50M
est: 5.04M (+108.3%)
4.04M
est: 3.60M (+12.3%)
3.53M
est: 3.89M (-9.2%)
7.39M
est: 4.17M (+77.4%)
4.06M
est: 5.83M (-30.3%)
7.50M
est: 25.22M (-70.3%)
4.85M
est: 10.78M (-55.0%)
13.17M
5.20M – 22.15M
+22.1% YoY
16.57M
4.83M – 29.57M
+25.9% YoY
64.65M
20.15M – 114.08M
+290.1% YoY
87.70M
27.34M – 154.75M
+35.6% YoY
90.91M
28.34M – 160.41M
+3.7% YoY
EPS
-4.33
est: -3.00 (-44.3%)
-1.90
est: -2.02 (+6.1%)
-2.74
est: -3.39 (+19.1%)
-3.86
est: -3.39 (-13.8%)
-3.11
est: -2.97 (-4.6%)
-0.89
est: -0.46 (-95.4%)
-0.29
est: -0.17 (-75.4%)
-0.62
est: -0.40 (-53.4%)
-0.80
est: 0.01 (-8,718.8%)
-1.66
est: 0.67 (-346.6%)
-1.04
est: -1.70 (+38.6%)
-0.32
est: -0.96 (+66.5%)
-0.84
est: -0.68 (-23.5%)
-1.13
est: -1.47 (+23.1%)
-1.18
est: -0.81 (-45.5%)
-0.84
est: -0.94 (+10.6%)
-0.98
est: -1.00 (+1.7%)
-0.91
est: -0.92 (+0.8%)
0.85
est: 1.61 (-47.2%)
-0.67
est: -0.61 (-10.7%)
-0.97
-1.93 – -0.10
-59.8% YoY
-1.02
-2.03 – -0.11
-5.0% YoY
-2.24
-4.46 – -0.24
-120.2% YoY
4.14
0.44 – 8.26
+285.2% YoY
4.57
0.48 – 9.11
+10.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-26 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-25 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-19 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-18 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-15 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-14 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
16.78M
OE per share TTM
0.81
Owner's Yield
5.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares Core SPI(R) ETF (CH) CHSPI.SW 0.01% 739.1K 0.10%
2 Avantis International Equity ETF AVDE 0.00% 605.9K 0.23%
3 Avantis Responsible International Equity ETF AVSD 0.00% 439.33 0.23%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-214.9K
Shares Outstanding
20.81M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ravi Anand Chief Medical Officer 1M —
Stefan Weber Chief Executive Officer & Executive Director 483.0K male
Filippo Moriggia Vice President of Operations — male
Laura Faravelli Vice President of Business Development — female
Roberto Galli Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology